Patents by Inventor David Bemis

David Bemis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • virulence factor compositions
    Patent number: 12138303
    Abstract: A multivalent immunogenic composition is provided, including one or more recombinant proteins selected from the group consisting of a recombinant attenuated Staphylococcus pseudintermedius Protein A (SEQ ID NO:2), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin S (SEQ ID NO:4), a recombinant attenuated Staphylococcus pseudintermedius Nucleotidase adenosine synthase protein (AdsA) (SEQ ID NO:6), a recombinant attenuated Staphylococcus pseudintermedius coagulase (SEQ ID NO:8), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin F (SEQ ID NO:10), and a recombinant attenuated Staphylococcus pseudintermedius exotoxin 15 (SEQ ID NO:12). Synthetic genes expressing the attenuated recombinant proteins and optimized for expression in E. coli are provided. Vaccines and therapeutic compositions comprising the one or more recombinant proteins are provided.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: November 12, 2024
    Assignee: University of Tennessee Research Foundation
    Inventors: Stephen A. Kania, David Bemis, Mohamed A. Abouelkhair
  • STAPHYLOCOCCUS PSEUDINTERMEDIUS VIRULENCE FACTOR COMPOSITIONS
    Publication number: 20210379173
    Abstract: A multivalent immunogenic composition is provided, including one or more recombinant proteins selected from the group consisting of a recombinant attenuated Staphylococcus pseudintermedius Protein A (SEQ ID NO:2), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin S (SEQ ID NO:4), a recombinant attenuated Staphylococcus pseudintermedius Nucleotidase adenosine synthase protein (AdsA) (SEQ ID NO:6), a recombinant attenuated Staphylococcus pseudintermedius coagulase (SEQ ID NO:8), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin F (SEQ ID NO:10), and a recombinant attenuated Staphylococcus pseudintermedius exotoxin 15 (SEQ ID NO:12). Synthetic genes expressing the attenuated recombinant proteins and optimized for expression in E. coli are provided. Vaccines and therapeutic compositions comprising the one or more recombinant proteins are provided.
    Type: Application
    Filed: July 30, 2021
    Publication date: December 9, 2021
    Inventors: Stephen A. Kania, David Bemis, Mohamed A. Abouelkhair
  • virulence factor compositions
    Patent number: 11141473
    Abstract: A multivalent immunogenic composition is provided, including one or more recombinant proteins selected from the group consisting of a recombinant attenuated Staphylococcus pseudintermedius Protein A (SEQ ID NO:2), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin S (SEQ ID NO:4), a recombinant attenuated Staphylococcus pseudintermedius Nucleotidase adenosine synthase protein (AdsA) (SEQ ID NO:6), a recombinant attenuated Staphylococcus pseudintermedius coagulase (SEQ ID NO:8), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin F (SEQ ID NO: 10), and a recombinant attenuated Staphylococcus pseudintermedius exotoxin 15 (SEQ ID NO: 12). Synthetic genes expressing the attenuated recombinant proteins and optimized for expression in E. coli are provided. Vaccines and therapeutic compositions comprising the one or more recombinant proteins are provided.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: October 12, 2021
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Stephen A. Kania, David Bemis, Mohamed A. Abouelkhair
  • STAPHYLOCOCCUS PSEUDINTERMEDIUS VIRULENCE FACTOR COMPOSITIONS
    Publication number: 20200246446
    Abstract: A multivalent immunogenic composition is provided, including one or more recombinant proteins selected from the group consisting of a recombinant attenuated Staphylococcus pseudintermedius Protein A (SEQ ID NO:2), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin S (SEQ ID NO:4), a recombinant attenuated Staphylococcus pseudintermedius Nucleotidase adenosine synthase protein (AdsA) (SEQ ID NO:6), a recombinant attenuated Staphylococcus pseudintermedius coagulase (SEQ ID NO:8), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin F (SEQ ID NO: 10), and a recombinant attenuated Staphylococcus pseudintermedius exotoxin 15 (SEQ ID NO: 12). Synthetic genes expressing the attenuated recombinant proteins and optimized for expression in E. coli are provided. Vaccines and therapeutic compositions comprising the one or more recombinant proteins are provided.
    Type: Application
    Filed: August 10, 2018
    Publication date: August 6, 2020
    Inventors: Stephen A. Kania, David Bemis, Mohamed A. Abouelkhair
  • Inhibitors of Staphylococcus pseudintermedius Sortase
    Publication number: 20190241675
    Abstract: Compounds inhibitory to Staphylococcus pseudintermedius Sortase A (SrtA) are identified. The compounds inhibit cell wall-associated protein anchoring to the bacterial cell wall, thus potentially reducing bacterial virulence.
    Type: Application
    Filed: August 28, 2018
    Publication date: August 8, 2019
    Inventors: David Bemis, Stephen Kania, Jerome Baudry, Manasi Balachandran